Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Crinetics Pharmaceuticals Inc. | Paltusotine - (CAREFNDR) | Carcinoid Syndrome | Phase 3 | Enrollment Initiation | Oral | Oncology |
| Crinetics Pharmaceuticals Inc. | Paltusotine - (PATHFNDR-1) | Acromegaly | Phase 3 | Data Released | Oral | Endocrinology |
| CRISPR Therapeutics AG | CASGEVY | Sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT) in patients aged 5-11 years | sNDA Filing | Ongoing | Intravenous | Hematology |
| CRISPR Therapeutics AG | CTX611 (SRSD107) | Total knee arthroplasty (TKA) | Phase 2 | Ongoing | Intravenous | Orthopedic |
| CRISPR Therapeutics AG | SRSD107 | Post-operative venous thromboembolism in patients undergoing total knee arthroplasty | Phase 2 | Enrollment Initiation | Oral | Anticoagulant |
| CSL Ltd. ADR | CSL112 -(AEGIS-II) | Acute myocardial infarction (AMI) | Phase 3 | Data Released | Intravenous | Cardiology |
| CSL Ltd. ADR | VMX-C001 - (EquilibriX-S) | Patients taking FXa DOACs who require urgent surgery | Phase 3 | Trial Planned | Oral | Anticoagulant |
| CSL Ltd. ADR | Kostaive (ARCT-154) | COVID-19 variant vaccine | Phase 3 | Data Released | Oral | COVID-19 |
